The five-year survival mark isn't the clean slate we pretend it is. In the scramble to kill a tumor, we're often just swapping a localized fire for the slow, systemic burn of accelerated senescence.

Chemotherapy and high-dose radiation aren't merely cytotoxic; they’re gerontogenic. They force a massive genotoxic debt onto the survivor, one that’s usually paid back through a ten-to-fifteen-year gap in biological age. We’re clearing the malignancy but leaving behind a wreckage of senescence-associated secretory phenotype (SASP) spillover. That’s what drives the early-onset frailty, cognitive decline, and cardiovascular failure we see in patients who are technically "cancer-free."

I’m particularly concerned about the stoichiometric exhaustion of our cellular repair machinery. When you hammer a system with DNA-damaging agents, you’re doing more than targeting fast-dividing cells. You’re draining the finite pool of E3 ligases and mitochondrial chaperones needed for basic maintenance. My work on UBE2L3-Parkin kinetics shows how fragile the mitophagy bridge really is. If you overwhelm it with the massive fragmentation chemo causes, you don't just feel sick for a few months—you risk losing the ability to clear cellular debris indefinitely. You effectively create a mitophagy-null phenotype in a body that’s expected to hold up for another forty years.

It raises a hard question: are we actually curing anyone, or are we just trading a quick death for a protracted, expensive dissolution?

We need to fund a shift toward co-administered geroprotection. We can't keep oncology and longevity research in separate silos. Unless we pair precision oncology with aggressive SASP-sequestration and proteostatic support, we aren't saving lives; we’re just making the exit ramp longer. I’m looking for collaborators who can help link clinical oncology data with longitudinal epigenetic aging clocks. We have the survivors. Now we have to make sure they have a future worth living through.